Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Sivaprasad, Sobha ^a   Crosby Nwaobi, Roxanne ^a   Esposti, Simona ^a   Peto, Tunde ^a   Rajendram, Ranjan ^a   Michaelides, Michel ^a,b   Hykin, Philip ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG RESPONSE; EXPLORATORY RESEARCH; HUMAN; LASER SURGERY; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RETINAL THICKNESS; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES COMPLICATIONS; FEMALE; HUMANS; MACULAR EDEMA; MALE; RECOVERY OF FUNCTION; RETINA; VISION, OCULAR;

EID: 84883162300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072755     Document Type: Article

References (20)

1. Pascolini D, Mariotti SP, (2012) Global estimates of visual impairment: 2010. Br J Ophthalmol 96: 614-618.
2. Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796-1806.
3. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077 e1035.
4. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, et al. (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-625.
5. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, et al. (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399-2405.
6. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, et al. (2010) Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 117: 2146-2151.
7. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, (2011) Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118: 609-614.
8. Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, et al. (2012) Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 130: 1153-1161.
9. Goyal S, Lavalley M, Subramanian ML, (2011) Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 249: 15-27.
10. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, et al. (2010) A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117: 1078-1086 e1072.
11. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, et al. (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130: 972-979.
12. Royal National Institute for the Blind (2013) Vision criteria for registration. Royal National Institute for the Blind.
13. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT, (2008) Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci 49: 4290-4296.
14. Ferris FL, (2010) A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology 117: 1512-1516.
15. National Institute for Health and Care Excellence (2013) Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237). In: Excellence NIfHaC, editor. London.
16. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398.
17. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S, (2011) Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. Journal of Ocular Pharmacology and Therapeutics 27: 373-377.
18. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, et al. (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicologic Pathology 27: 536-544.
19. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, et al. (2008) Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 28: 1053-1060.
20. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, et al. (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26: 262-269.